30 March 2022 : Clinical Research
Follow-Up of 108 Patients with Chronic Hepatitis B Virus Infection Treated with Polyethylene Glycol-Conjugated Derivatives of Interferon-Alpha and Monitoring of Off-Treatment Virological Relapse
Liyang Zhou1ABCDEF, Qin He1CEF, Xitao Liu2DEF, Xiaoan Yang3BC, Xueting Ou3EF, Bing Situ2DF, Yueping Li4DE, Xingfei Pan1DEFG*, Qihuan Xu3AEDOI: 10.12659/MSM.934785
Med Sci Monit 2022; 28:e934785

Figure 3 (A) Difference in the cumulative rate of clinical suppression between A1 and group A2 (P<0.01). Group A1, the normal alanine aminotransferase (ALT) value group at 24 weeks after off-therapy; Gropu A2, the abnormal ALT value group at 24 weeks after off-therapy. (B) Difference in the cumulative rate of clinical suppression between B1 and group B2 (P=0.035). Group B1, patients with a history of antirival treatment. Group B2, patients without a history of antirival treatment. (C) Difference in the cumulative rate of clinical suppression among group C1, C2 and C3 (P=0.001). Group C1, HBsAg ≤500 COI, the low HBsAg value group at 48 weeks of PEG-IFN-α treatment. Group C2, HBsAg 500–6000 COI, the middle HBsAg value group at 48 weeks of PEG-IFN-α treatment. Group C3, HBsAg >6000 COI, the high HBsAg value group at 48 weeks of PEG-IFN-α treatment. HBsAg – hepatitis B surface antigen; PEG-IFN-α – pegylated interferon-alpha.